Università Campus Bio-Medico di Roma is a for-profit college situated in Trigoria, founded in 1993 and promoted by the Beatus Alvaro del Portillo, according to the principles of the Catholic prelature of the Opus Dei.

During the past decade, Universita Campus Bio Medico Di Roma conducted 67 clinical trials. In the 10-year time frame, 67 clinical trials started and 17 clinical trials were completed, i.e. on average, 25.4% percent of trials that started reached the finish line to date. In the past 5 years, 33 clinical trials started and 13 clinical trials were completed. i.e. 39.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universita Campus Bio Medico Di Roma" #1 sponsor was "Campus Bio-Medico University" with 24 trials, followed by "Janssen Research & Development, LLC" with 7 trials sponsored, "Celgene" with 4 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 3 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universita Campus Bio Medico Di Roma" #1 collaborator was "Campus Bio-Medico University" with 3 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Center for Outcomes Research and Clinical Epidemiology, Italy" with 2 trials as a collaborator, "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico" with 2 trials as a collaborator and "Gruppo Italiano Malattie EMatologiche dell'Adulto" with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Universita Campus Bio Medico Di Roma" are "Crohn Disease" (4 trials), "Crohn's Disease" (4 trials), "Leukemia" (3 trials), "Metastatic Colorectal Cancer" (3 trials) and "Type 1 Diabetes" (3 trials). Many other conditions were trialed in "Universita Campus Bio Medico Di Roma" in a lesser frequency.

Most popular intervention types in "Universita Campus Bio Medico Di Roma" are "Drug" (69 trials), "Other" (18 trials), "Procedure" (10 trials), "Biological" (6 trials) and "Device" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Cisplatin" (4 trials), "Docetaxel" (3 trials), "GED-0301" (3 trials) and "Gemcitabine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Universita Campus Bio Medico Di Roma" are 81 trials for "All" genders, 15 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Universita Campus Bio Medico Di Roma". undefined are not yet recruiting, 23 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in Universita Campus Bio Medico Di Roma, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Universita Campus Bio Medico Di Roma, 3 "Phase 1" clinical trials were conducted, 36 "Phase 2" clinical trials and 35 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 13 trials that are defined as “Not Applicable".